Le Lézard
Classified in: Health
Subjects: SBS, MAT

Cannabis Genetics Company Phylos Announces Elite Seeds: High-Potency, Production-Ready F1 Hybrid Seeds for Controlled Environments


Elite cannabis seeds produce uniform genetics that outperform clones with higher yields, lower production costs, stress tolerance, and HLVd-resistance

PORTLAND, Ore., April 2, 2024 /PRNewswire/ -- Cannabis genetics company Phylos® has added 10 Elite varieties to its growing menu of proprietary F1 hybrid seeds. Phylos Elites produce uniform plants that outperform clones and improve the economics of commercial indoor and controlled-environment operations.

"Elite seeds generate vigorous plants that produce premium, standardized consumer products while reducing notoriously high costs of operating indoor and greenhouse grows," noted Ralph Risch, Phylos CEO. "To our knowledge, Elites are the first seeds bred and validated to perform in high-stress, rapid cycle time, controlled environments."

Elite seeds positively impact operations in multiple ways:

"Compared to clones, the use of Phylos seeds in our preliminary trials contributed to a sizable reduction in our labor and plant care costs," said Beena Goldenberg, CEO of Organigram. "We expect that with the continued expansion of seed-based grow in our facility, we will see significant and continued improvements to our bottom line," she added.

Phylos accelerates the conventional breeding process by using genetic markers to look for plants with desirable consumer and agronomic traits. By selecting plants at the seedling stage, Phylos can analyze the same number of plants as a facility 50x larger. Successive cycles of inbreeding and high throughput genotyping tools ensure the most inbred, stable parent lines are used to create truly uniform F1 hybrid seeds.

"I am very happy with the results from our trial of Phylos Elite seeds. We are expanding our work with Phylos due to the high-quality flower, comparable yields to clones, and absence of hermaphroditic issues or genetic instability," said Rachel Porter, Director of Research and Development at StateHouse Holdings. "This reaffirms our belief that F1 Hybrid Seeds hold immense promise for the industry, offering a pathway to cultivate top-tier flower while also eliminating the costs tied to stock management and clone propagation."

Phylos F1 hybrid Elite seeds can be easily trialed in the same room as clones for cultivators to quickly see how seeds are the future of large-scale, cost-efficient cannabis production. They are available for trials and purchase at phylos.bio.

About Phylos
Phylos is a cannabis genetics company that empowers growers of all sizes to produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seedtm: premium, phenotypically stable, fully-feminized F1 hybrid seed lines that deliver exceptional flower quality, potency, vigor, and yield.

Phylos also leverages its proprietary, patent-pending technology to provide partners with unparalleled rare cannabinoid genetics. It creates natural, safe, and effective ingredients under its Natural Natural brand utilizing its cultivation, extraction, and formulation expertise. Natural Natural THCV varieties power a high-quality supply chain of naturally derived THCV.

Resources:

Media Contact:
Beth Graham
[email protected]

SOURCE Phylos


These press releases may also interest you

at 06:05
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2024. Amounts are expressed in U.S. dollars. Total net revenue was $50.3 million for the three months ended March 31,...

at 06:00
Isarna Therapeutics today announced upcoming oral presentations at the OIS Retina Innovation Summit on May 4th and the Association for Research in Vision and Ophthalmology (ARVO) Meeting on May 7th, both in Seattle, WA. Isarna's Chief Medical...

at 06:00
U.S. Dermatology Partners and The University of Texas at Tyler School of Medicine are proud to announce their partnership in establishing a new Department of Dermatology. This collaboration aims to improve the health and well-being of East Texans...

at 06:00
Marpai, Inc. ("Marpai" or the "Company") , an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, today announced...

at 06:00
In a significant advancement for minimally invasive pain management, PainTEQ has been awarded two new patents for its pioneering LinQ® procedure, further solidifying its position as a leader in sacroiliac (SI) joint dysfunction treatment. These...

at 06:00
Genomenon, a genomic intelligence company, has partnered with Pharming Group in an effort to make variant data on the PIK3CD and PIK3R1 genes available to genetic testing labs, as well as clinicians and researchers, worldwide. This data enables...



News published on and distributed by: